[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN112089783B - Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity - Google Patents

Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity Download PDF

Info

Publication number
CN112089783B
CN112089783B CN202010854230.XA CN202010854230A CN112089783B CN 112089783 B CN112089783 B CN 112089783B CN 202010854230 A CN202010854230 A CN 202010854230A CN 112089783 B CN112089783 B CN 112089783B
Authority
CN
China
Prior art keywords
parts
blood
obesity
traditional chinese
mixed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010854230.XA
Other languages
Chinese (zh)
Other versions
CN112089783A (en
Inventor
胡元会
崔翰明
师帅
张秋燕
宋庆桥
吴华芹
魏艺
耿彦婷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guanganmen Hospital of CACMS
Original Assignee
Guanganmen Hospital of CACMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guanganmen Hospital of CACMS filed Critical Guanganmen Hospital of CACMS
Priority to CN202010854230.XA priority Critical patent/CN112089783B/en
Publication of CN112089783A publication Critical patent/CN112089783A/en
Application granted granted Critical
Publication of CN112089783B publication Critical patent/CN112089783B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/718—Coptis (goldthread)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A61K36/424—Gynostemma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A61K36/428—Trichosanthes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A61K36/8888—Pinellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/894—Dioscoreaceae (Yam family)
    • A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses an application of a traditional Chinese medicine composition in preparing a medicament for preventing and treating obesity, wherein the composition comprises the following raw materials: coptis root, frankincense, myrrh, dragon's blood, rhizoma pinellinae praeparata, fructus trichosanthis, gynostemma pentaphylla, poria cocos and dioscorea nipponica. The traditional Chinese medicine composition disclosed by the invention is directed at the process and pathological mechanism of fat generation and accumulation in vivo in the development process of phlegm-blood stasis interlocking obesity, and has the advantages of reducing phlegm and activating blood, descending turbidity and dredging collaterals, achieving the purposes of improving obesity and losing weight, being obvious in curative effect on preventing and treating the phlegm-blood stasis interlocking obesity, quick in effect taking, small in toxic and side effects, safe, efficient, stable, simple in preparation process, suitable for industrial production and easy to popularize. The invention provides a new medicine source for preventing and treating phlegm-blood stasis type obesity and complications thereof.

Description

Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity
Technical Field
The invention relates to the field of medicines, relates to a medicine or health-care food for preventing and treating obesity, and particularly relates to application of a traditional Chinese medicine composition in the medicine or health-care food for preventing, relieving and treating obesity.
Background
Obesity is a complex multifactorial disease. Over the past 30 years, the prevalence of obesity worldwide has increased by 27.5% in adults and 47.1% in children, so that nearly one third of the world's population is currently classified as overweight or obese. The occurrence of obesity is closely related to heredity, lifestyle, eating habits and the like, and is also influenced by factors such as urban development, consumption patterns, social economy, culture and the like. Obesity can cause many metabolic-related diseases such as stroke, hypertension, diabetes, etc., and is a risk factor that leads to the development of various disease complications. Obesity not only brings harm to the body, but also increases the medical cost of patients, and causes economic burden to society. The incidence of obesity increases in all ages and sexes regardless of geographic location, ethnicity or socioeconomic status. The prevalence of obesity is generally higher in the elderly and women. Although the absolute prevalence of overweight and obesity varies widely, trends are similar in various regions and countries. For some developed countries, the prevalence of obesity has seemed to have leveled off over the last few years. In epidemiological studies, Body Mass Index (BMI) is commonly used to define overweight and obesity. However, for any given BMI value, the sensitivity of BMI is low and there is a large individual variation between the percentage of fat in the body, due in part to age, gender and race. For example, asian people have a higher percentage of body fat than caucasian people for the same BMI. Higher cardiometabolic risk is also associated with the localization of excess fat in visceral adipose tissue and ectopic depots (e.g., muscle and liver). Relying solely on BMI to assess its prevalence may hinder future interventions directed to the prevention and control of obesity. The actual condition of obesity may be more prevalent and urgently of concern than large epidemiological studies have shown.
At present, modern medical treatment of obesity mainly comprises life style intervention and medical intervention, and the medical intervention comprises drug treatment, operation treatment, intestinal flora intervention and the like. Lifestyle interventions mainly include fasting therapy, exercise therapy, behavioral therapy, and the like. The drug therapy mainly comprises targeted nervous system drugs such as phentermine and the like, targeted adipose tissue drugs such as leptin and analogues thereof and the like, targeted digestive system drugs such as orlistat and the like, targeted renal drugs such as sodium-glucose cotransporter 2 inhibitors and the like, targeted immune system drugs and the like. Surgical interventions include gastric bypass, vertical sleeve gastrectomy, and the like. The intestinal flora intervention comprises oral intestinal bacteria Akkermansia muciniphila, bifidobacterium and the like. The lifestyle intervention has higher willpower requirement on patients, the application range is limited, the effectiveness of the weight-reducing medicine is lower, the safety is low, the medication period is long, and the patients are difficult to persist for a long time. Surgical intervention presents risks and contraindications. The effectiveness and safety of gut flora intervention has not been widely validated. The development and validation of effective therapies for obesity continues to be a long-felt need.
The traditional Chinese medicine recognizes that obesity is mainly considered as phlegm-dampness, and the phlegm-dampness enters collaterals to form stasis after a long-term disease, and finally forms the syndrome of intermingled phlegm and blood stasis. The treatment mainly comprises traditional Chinese medicine compound treatment, acupuncture treatment and other therapies such as catgut embedding, massage, scraping and the like. More documents report positive results, but the prescription selection and the like of the Chinese medicinal composition have stronger individual specificity and relatively lower reproducibility and popularization.
With the progress of modern medical science and technology means, people can more deeply know the obesity, the obesity causes serious consequences, and a large number of obese patients are not completely cured at present. Therefore, the development of a Chinese medicinal preparation which is targeted to the pathogenic link by applying the rich experience and theory of the traditional Chinese medicine is important for the future research to provide scientific basis for further improving the clinical curative effect.
The current similar products are in the market: the weight-losing tablets, the weight-losing and fat-reducing pills, the weight-losing tongsheng tablets and the like are common similar products in the market at present. The prescription mainly takes medicines with the functions of promoting digestion and relaxing bowels such as rhubarb, hawthorn, alisma orientale and the like as main components, and the medicine has insufficient importance on the main pathological factor of phlegm-dampness and is difficult to adapt to patients with poor spleen and stomach functions.
Disclosure of Invention
The invention aims to solve the technical problems of the existing products for treating and preventing obesity, provides the performance and the efficacy of a traditional Chinese medicine composition in the aspects of preventing and treating obesity, and particularly provides a new application of the traditional Chinese medicine composition in treating phlegm-blood stasis mutual-connection type obesity, namely a new application in medicines or health-care products for treating the phlegm-blood stasis mutual-connection type obesity.
In order to achieve the purpose of the present invention, in one aspect, the present invention provides an application of a traditional Chinese medicine composition in preparation of a drug or a health product for preventing or/and treating obesity, wherein the traditional Chinese medicine composition comprises the following raw materials: coptis root, frankincense, myrrh, dragon's blood, rhizoma pinellinae praeparata, fructus trichosanthis, gynostemma pentaphylla, poria cocos and dioscorea nipponica.
Wherein the obesity is phlegm-blood stasis type obesity.
In the process of screening natural medicines for preventing and treating obesity (particularly phlegm-blood stasis interlocking obesity), the inventor finds that the traditional Chinese medicine composition has the effects of obviously inhibiting blood fat deposition of blood vessels, reducing blood fat plaques on the inner walls of the blood vessels, maintaining the inner diameter of the blood vessels or increasing the inner diameter of the blood vessels at the end of contraction and relaxation and preventing blood vessel blockage.
In particular, the raw material medicines comprise the following components in parts by weight: 3-12 parts of coptis chinensis, 6-15 parts of frankincense, 6-15 parts of myrrh, 3-12 parts of dragon's blood, 3-9 parts of rhizoma pinellinae praeparata, 6-15 parts of fructus trichosanthis, 10-30 parts of gynostemma pentaphylla, 10-30 parts of poria cocos and 10-30 parts of dioscorea nipponica.
Particularly, the weight part ratio of the raw material medicines is preferably as follows: 3-9 parts of coptis chinensis, 6-12 parts of frankincense, 6-12 parts of myrrh, 3-9 parts of dragon's blood, 6-9 parts of rhizoma pinellinae praeparata, 9-15 parts of fructus trichosanthis, 15-30 parts of gynostemma pentaphylla, 15-30 parts of poria cocos and 15-30 parts of dioscorea nipponica.
In particular, the raw material medicines comprise the following components in parts by weight: coptis root 6, frankincense 12, myrrh 12, dragon's blood 6, rhizoma pinellinae praeparata 9, trichosanthes kirilowii 15, gynostemma pentaphylla 30, poria cocos 15 and dioscorea nipponica 30.
In particular, the frankincense is selected from stir-fried frankincense, preferably stir-fried frankincense with vinegar; the myrrh is prepared by parching Myrrha, preferably parching Myrrha with vinegar; the rhizoma Pinelliae is rhizoma Pinelliae Preparata; the fructus trichosanthis is selected from whole fructus trichosanthis.
The rhizoma pinellinae praeparata is prepared by processing raw pinellia ternate with liquorice, lime and the like in summer in a modern processing technology, so that the toxicity of the raw rhizoma pinellinae praeparata can be obviously reduced, and the effects of drying dampness and reducing phlegm are enhanced. Compared with the properties of pericarpium Trichosanthis, semen Trichosanthis and radix Trichosanthis, fructus Trichosanthis has the effects of relieving chest stuffiness, resolving hard mass, removing phlegm and resolving stagnation. Crude frankincense and myrrh are usually used externally, and are more suitable for oral administration after being fried, and are used for regulating qi and activating blood circulation.
In clinic, the obese patient often has phlegm-turbidity and blood stasis together, and the channels are blocked, so other complications are easy to occur. Based on the treatment principle of treating phlegm and blood stasis at the same time, the invention takes the concept of reducing phlegm and activating blood, and descending turbidity and dredging collaterals as well as the formula named as 'Qi Long Xue Mai Jian Fang'. Wherein, the dragon's blood which is good at promoting blood circulation and the yam which has stronger function of dredging collaterals are used as monarch drugs, the dragon's blood is named as ' Qi Jie ' in the ancient times, and the dragon's character of the yam is named as ' Qi Long '. Snakegourd fruit has the effects of relieving chest stuffiness and regulating qi, eliminating phlegm and resolving masses, frankincense has the effects of regulating qi and activating blood, myrrh has the effects of removing blood stasis and regulating blood, and helps monarch drugs to activate blood, and the snakegourd fruit and the myrrh are used as ministerial drugs together. Pinellia tuber, rhizoma Pinelliae is bitter and pungent with the effect of warming and drying, eliminating dampness and phlegm, regulating stomach and lowering adverse qi, and has the effects of helping trichosanthes kirilowii maxim reduce phlegm and dissipate stagnation, and poria cocos, invigorating spleen and eliminating dampness, and helping to reduce phlegm; gynostemma pentaphylla has the effects of invigorating spleen, regulating qi, tonifying qi, activating blood circulation and enhancing properties of monarch drugs and minister drugs, and is an adjuvant drug together. Phlegm and blood stasis are combined together, so they tend to stagnate and transform into heat, and Huang Lian is bitter in taste and cold in nature, and can clear heat after drying dampness, so it is a guiding drug. The medicines in the formula are used for treating phlegm and blood stasis, and have the effects of reducing phlegm and activating blood, descending turbid and dredging collaterals, and are particularly suitable for treating phlegm and blood stasis type obesity.
Sanguis Draxonis is also called dragon's blood resin containing wood ethanol extract of dracaena cochinchinensis (lour.) nakai of Liliaceae, and has effects of promoting blood circulation, dispelling blood stasis, relieving pain, stopping bleeding, promoting granulation, and healing sore; the oral administration is mainly used for treating blood stasis swelling and pain, amenorrhea and dysmenorrheal, the external application is mainly used for treating traumatic hemorrhage, unhealed ulcer and anal fistula swelling and pain, and the oral administration is one of the famous traditional Chinese medicines for promoting blood circulation and removing blood stasis. The dragon's blood contains various compounds, and the efficacy of the dragon's blood obtained by different extraction processes is different due to different purities and types of the compounds. Dragon's blood is a "blood-activating saint drug", and is increasingly used clinically as a traditional Chinese medicine for activating blood and removing stasis. In recent years, dragon's blood is adopted to treat cardiovascular diseases clinically, and the dragon's blood has a better curative effect. The research carries out systematic chemical component research on the dragon's blood, 20 compounds are separated and identified, and the flavonoid compounds are proved to be the main effective components for activating blood and removing blood stasis. Clinical application shows that the dragon's blood can improve the symptoms of angina pectoris of old myocardial infarction patients, improve microcirculation, reduce the viscosity of whole blood and blood plasma, adjust the balance of TXB2/PGF1 alpha, increase myocardial oxygen supply, contribute to improving cardiac function and is an effective medicament for preventing and treating coronary heart disease. Modern medical research also proves that the dragon's blood has the functions of bidirectionally regulating hemostasis, activating blood and the like.
Chuanshan is bitter in taste and slightly cold in nature, enters liver and lung meridians, has the main effects of promoting blood circulation and removing obstruction in collaterals, is the rhizome of dioscorea nipponica Makino of dioscoreaceae, also known as Chuanshan yam, Dioscorea nipponica, Chuanhong, Dioscorea opposita, Curcuma rhizome, and Xue, etc. Is mainly used for treating rheumatic arthralgia; numbness of limbs; chest stuffiness and pain; chronic tracheitis; traumatic injury; abuse; abscess and swelling. The main components of Ningpo Yam rhizome include dioscin, fine dioscin, sarsasaponin, 25-D-spirost-3, 5-diene, p-hydroxybenzyl tartaric acid, etc. Yam rhizome has been used as important industrial material for steroid hormone medicine and coronary heart disease resisting saponin medicine. Modern pharmacological research proves that the total saponin components have various pharmacological effects of regulating immunity, improving cardiovascular function, eliminating phlegm, resisting tumor, resisting inflammation, relieving pain and the like. It is often used in folk to soak in wine or decoct for oral administration, and can be used for treating pain in chest, lumbar sprain, senile lumbago and skelalgia, and rheumatic arthritis.
In the invention, for the state of phlegm stagnation and mutual combination caused by long-term obesity and water retention and blood stasis, the dioscorea nipponica makino can dredge the channels and collaterals and effectively promote the body to recover normal metabolism.
Ban Xia is pungent in flavor, warm in nature, toxic and enters spleen, stomach and lung meridians. Cloud of famous physicians' bibliography: pinellia ternate has the effects of eliminating phlegm and phlegm, lowering adverse flow of qi, relieving epigastric and thoracic diaphragms, relieving cough and ascending qi, treating urgent pain and lump in the lower heart, and preventing vomiting due to frequent vomiting, and has the effects of eliminating dampness and phlegm, lowering adverse flow of qi and preventing vomiting, relieving lump and eliminating stagnation and relieving swelling and pain for external use. Ban Xia is famous for resolving phlegm, i.e. it has pungent flavor, so it can be used to resolve phlegm even when the stagnation of water-damp phlegm-phlegm is obstructed, so it is said to descend adverse flow of qi and resolve phlegm. The onset of obesity is closely related to the core pathogenesis of phlegm-dampness, and if the pungent action of ban Xia is obtained, the phlegm and fluid can be reduced.
Snakegourd fruit is sweet in nature, sweet in flavor and cold in nature, and has the effects of clearing lung, eliminating phlegm, regulating qi and relieving chest stuffiness. Snakegourd fruit is a perennial grass vine of the cucurbitaceae family, and the traditional Chinese medicine snakegourd fruit is mature pericarp and seed thereof. The fruit is cut off with the handle in autumn when the fruit is ripe, and then hung and dried for application. According to analysis, the snakegourd fruit contains components such as triterpenoid saponin, organic acid, resin, saccharide, fatty oil, pigment and the like. Pharmacological research shows that the snakegourd fruit can reduce blood cholesterol and triglyceride. The phlegm-resolving efficacy of the snakegourd fruit can assist the pinellia tuber and commonly aim at the pathological elements of the 'phlegm-dampness' of obese people.
Frankincense is slightly cold in nature, pungent, bitter and warm in taste. It enters heart, liver and spleen meridians and has the actions of promoting blood circulation and qi circulation; inducing menstruation to relieve menalgia; the efficacy of detumescence and promoting granulation. Can be used for treating pain of heart and abdomen, spasm of tendons and vessels, traumatic injury, skin ulcer, carbuncle, and swelling and pain; it can be used topically for detumescence and granulation promotion. The main components of frankincense include resin, gum and volatile oil, which are good at moving and promoting qi and blood circulation, and myrrh is neutral in property and emphasizes on bitter taste and purgation, blood dissipation and blood stasis removal. The main components of mastic resin are free a, beta-mastic acid, combined mastic acid, mastic resin hydrocarbon, O-acetyl-beta-mastic acid, O-acetyl-a-mastic acid, etc.; modern pharmacological research shows that the frankincense volatile oil has an obvious analgesic effect; the frankincense can also promote the increase of multinucleated white blood cells, so as to phagocytize dead blood cells and dead cells, improve metabolism and further play a role in diminishing inflammation and preventing corrosion.
The myrrh is bitter in taste and neutral in nature, enters liver channel, has the effects of removing blood stasis and relieving pain, and externally dispersing swelling and promoting granulation, and is mainly used for treating traumatic blood stasis and swelling pain, carbuncle and cellulitis swelling pain, chest and abdomen pain; it is indicated for long-term sore without astringency. The main components of myrrh comprise resin, volatile oil, gum and the like, wherein most of myrrh resin can be dissolved in ether, wherein: the insoluble part contains alpha and beta bisaboloic acid, and the soluble part contains alpha, beta and gamma bisaboloic acid, alpha and beta bisabolol, etc.; the volatile oil is easily resinified in air, and contains eugenol, m-cresol, cumaldehyde, allyl, dipentene, limonene, cinnamaldehyde, and hamoumarin; hydrolyzing the gum to obtain arabinose, galactose and xylose.
Modern pharmacological research shows that the myrrh water extract has an inhibiting effect on dermatophytes; the myrrh decoction can increase blood flow and reduce vascular resistance; moreover, the oleoresin can reduce the cholesterol content of male rabbit hypercholesterolaemia (caused by feeding hydrogenated vegetable oil), prevent plaque formation, and reduce rabbit weight. Similar to other oleoresin-containing substances, myrrh (usually in tincture) has some local irritation, and can be used in oral cavity lotion, or used for stimulating intestinal peristalsis when stomach and intestine are weak. .
The compatibility of Ru Xiang and Mo Yao is known in the formula Ru Xiang Zhi san (therapeutic treatment guideline). Frankincense is slightly cold in nature, pungent, bitter and warm in taste. Enter heart, liver and spleen meridians and have the functions of promoting blood circulation, relieving pain, eliminating swelling and promoting granulation. It is an essential drug for traumatology, and can be used for treating pain of heart and abdomen, spasm of muscles and tendons, traumatic injury, sore, carbuncle, and swelling and pain; modern pharmacological actions: relieving pain, diminishing inflammation, etc. Frankincense, pungent and warm in flavor and fragrant in flavor, is good at moving and moving, promoting qi and blood circulation, and myrrh is mild in property and emphasized on bitter in flavor and purgation, dissipating blood stasis. The compendium of materia Medica says: ru Xiang has the action of activating blood and Mo Yao has the action of dispersing blood, so they are indicated for each herb because they can alleviate pain, resolve swelling and promote tissue regeneration. The text of materia Medica: taking the medicine for a long time can relax the fascia, promote blood circulation, strengthen teeth and teeth, and grow beard and hair. Frankincense and myrrh are both traditional Chinese medicines with the functions of promoting blood circulation and removing blood stasis, frankincense is warm in nature, myrrh is flat in nature, the frankincense and the myrrh are both pungent, bitter and fragrant in flavor, and enter heart, liver and spleen channels, and the frankincense and the myrrh are clinically commonly used pairs and have better curative effects of improving heart and abdomen pain, rheumatic arthralgia, amenorrhea and dysmenorrheal, traumatic injury and blood stasis pain and the like. It can be used to treat various pains of heart, stomach, abdomen and costal region and joints of limbs.
Natural Chinese herbal medicine gynostemma pentaphylla, also called fiveleaf gynostemma herb, liquorice and American ginseng. Sweet, sweet and slightly cold in nature and taste. Enter lung, spleen, stomach, heart, kidney and large intestine meridians. Has the effects of invigorating spleen, regulating qi, invigorating qi, promoting blood circulation, eliminating phlegm, and relieving cough. It is commonly indicated for chest stuffiness and pain due to qi deficiency, blood stasis and meridian obstruction. Can be used for treating angina pectoris, myocardial infarction, ischemic apoplexy, cerebral hemorrhage sequelae, vascular headache and tumor of coronary heart disease. The effective component of Gynostemma pentaphyllum Makino is gypenoside, which is isomer of protopanaxadiol and protopanaxatriol. It has obvious functions of lowering cholesterol, triglyceride and low density lipoprotein, raising high density lipoprotein, promoting the action of oxidase in human body, raising cell activity and dilating blood vessel. It has effects in regulating fat metabolism and preventing lipid deposition on blood vessel wall. Therefore, the composition has good prevention and treatment effects on protecting vascular endothelial cells and preventing atherosclerosis. Modern pharmacology indicates that the gypenosides can inhibit collagen-induced platelet release S-HT and release thromboxane A2, increase the CAMP level in platelets and reduce blood viscosity. Therefore, the product has very important significance for preventing and treating coronary heart disease and cerebral thrombosis. Through the research of scholars at home and abroad, the gypenosides have the effects of resisting platelet aggregation, reducing thromboxane B2(TXB2) and 5 hydroxytryptamine released by platelets, resisting oxygen free radicals, resisting lipid peroxidation, protecting ischemic myocardial injury, reducing blood fat and blood sugar and the like. The research proves that the gypenoside and the ginsenoside are the same compound, and the functions of the gypenoside in improving myocardial ischemia and promoting the recovery of ischemic myocardium are related to the components containing the ginsenoside.
Poria, commonly known as Poria cocos, pine tuckahoe and Poria cocos wolf, is a fungus plant parasitic on pine roots, and is shaped like a sweet potato with black brown outer skin and white or pink inner side. The original biomass is dry sclerotium of Poria cocos (Schw.) wolf of Polyporaceae, and is mainly parasitic on root of Pinus massoniana or Pinus densiflora. Produced in Yunnan, Anhui, Hubei, Henan, Sichuan and other places. It can play its unique role regardless of cold, warm, wind and dampness. Poria has sweet and light taste and mild nature, and has effects of promoting diuresis, eliminating dampness, invigorating spleen, regulating stomach function, calming heart and tranquilizing mind. Modern medical research: the tuckahoe can enhance the immunity of the organism, and the tuckahoe can achieve the effects of regulating qi, activating blood, strengthening spleen and reducing phlegm when being used together with various medicines.
The golden thread is bitter and cold in nature and flavor, and enters heart, gallbladder, spleen, stomach and large intestine, and the pearl sac (pearl sac) records: "purging heart fire, epigastric fullness". "Renzhai Zhi Fang": has the functions of removing heart orifice and blood stasis and clearing heat and drying dampness, purging fire and removing toxicity. Recent pathological research shows that the coptis has the function of resisting lipid oxidation. Research shows that the coptis chinensis has strong lipid peroxidation inhibition effect in vivo and in vitro, and the lipid peroxidation inhibition effect can be realized by removing hydroxyl free radicals. When the rats are fed with the high-fat feed, the coptis chinensis can effectively reduce the blood fat and the level of the hypersensitive C-reactive protein of the experimental rats and inhibit inflammatory reaction. The chemical components of the coptis chinensis comprise alkaloid and lignan, and also comprise phenolic acid, volatile oil, coumarin, terpenes, steroids, polysaccharide, resin, protein, starch, pigment and some trace elements. The most studied is alkaloids with abundant pharmacological activity. Berberine is the main chemical component of coptis chinensis, and researches show that the berberine has a remarkable effect of inhibiting obesity. Mainly comprises inhibiting preadipocyte differentiation and adipogenesis, inducing the transformation of white fat cells to brown fat cells, increasing energy consumption and regulating intestinal flora. In addition, berberine also has certain effect on obesity related complications, such as reducing blood sugar, reducing blood lipid, regulating chronic inflammation, improving insulin resistance, etc.
The traditional Chinese medicine composition is prepared by the following method:
1) mixing Coptidis rhizoma, Olibanum, Myrrha, rhizoma Pinelliae, fructus Trichosanthis, herba Gynostemmatis, Poria, and Ningpo Yam rhizome, adding water, heating the mixture, extracting for 2-4 times, filtering, and mixing filtrates to obtain mixed extractive solution;
2) concentrating the mixed extract to prepare a mixed concentrated solution;
3) pulverizing sanguis Draxonis to obtain sanguis Draxonis powder;
4) mixing the concentrated solution with sanguis Draxonis powder.
Wherein the raw materials in the steps 1) and 3) are prepared from the following raw materials in parts by weight: 3-12 parts of coptis chinensis, 6-15 parts of frankincense, 6-15 parts of myrrh, 3-12 parts of dragon's blood, 3-9 parts of rhizoma pinellinae praeparata, 6-15 parts of fructus trichosanthis, 10-30 parts of gynostemma pentaphylla, 10-30 parts of poria cocos and 10-30 parts of dioscorea nipponica.
Particularly, the weight parts of the raw materials are as follows: 3-9 parts of coptis chinensis, 6-12 parts of frankincense, 6-12 parts of myrrh, 3-9 parts of dragon's blood, 6-9 parts of rhizoma pinellinae praeparata, 9-15 parts of fructus trichosanthis, 15-30 parts of gynostemma pentaphylla, 15-30 parts of poria cocos and 15-30 parts of dioscorea nipponica, and preferably: coptis root 6, frankincense 12, myrrh 12, dragon's blood 6, rhizoma pinellinae praeparata 9, trichosanthes kirilowii 15, gynostemma pentaphylla 30, poria cocos 30 and dioscorea nipponica 30.
Wherein, the weight ratio of the total weight of the raw material mixture to the weight of the added water in each heating and extracting process in the step 1) is 1: 1-15.
Particularly, the heating extraction temperature is 60-100 ℃, and preferably 80-100 ℃; the heating extraction time is 1-5 h/time.
Particularly, the raw material mixture is added with water and uniformly mixed, and then is soaked for 20-90min, and then is heated and extracted.
Particularly, the soaking time is preferably 30-60min, and more preferably 30 min.
Wherein, the heating extraction in the step 1) is carried out according to the following steps:
1A) mixing the raw materials of coptis chinensis, frankincense, myrrh, pinellia ternate, snakegourd fruit, gynostemma pentaphylla, poria cocos and dioscorea nipponica, adding water for soaking, wherein the weight ratio of the added water to the mixed raw materials is (1-15) to 1, soaking for 20-90min, and then carrying out first heating extraction at the temperature of 60-100 ℃ for 1-5 h;
1B) filtering the mixed system for the first extraction to obtain a first extracting solution; adding water into the residue at least 1 time, and continuously extracting for at least 1 time, wherein the ratio of the weight of water added to the weight of the mixed raw materials is (1-15):1, the extraction temperature is 60-100 deg.C, and the extraction time is 1-5 h;
1C) filtering, and mixing filtrates to obtain the mixed extractive solution.
In particular, the soaking time in the step 1A) is preferably 30-60min, and more preferably 30 min; the ratio of the weight of the added water to the weight of the mixed raw materials is preferably (5-15):1, more preferably (6-12):1, and still more preferably (6-9): 1; the heating extraction time is preferably 2-5 h; the heating extraction temperature is preferably 80-100 ℃; the ratio of the weight of water added in each time to the weight of the mixed raw materials in the step 1B) is preferably (1-5) to 1; the extraction time is preferably 1-3h per heating; the temperature for extraction by heating is preferably 80-100 ℃.
Wherein the concentration treatment in the step 2) is to perform reduced pressure evaporation concentration on the mixed extracting solution in a vacuum state to remove water, wherein the concentration temperature is 80-100 ℃, preferably 80 ℃, and the relative pressure during concentration is-0.05 to-0.1 MPa, preferably-0.05 to-0.095 MPa, and more preferably-0.07 MPa.
In particular, the concentration treatment in step 2) is a heating evaporation treatment of the mixed extract under normal pressure, i.e. under an absolute pressure of 1atm, the combined water extract is heated to evaporate water therein for concentration.
Wherein the relative density of the mixed concentrated solution in the step 2) is 1.05-1.5, preferably 1.1-1.5, and further preferably 1.1-1.3; the particle size of the dragon's blood powder in the step 3) is less than 15 mu m.
Particularly, the pulverization in the step 3) is selected to be superfine pulverization; the particle diameter of the sanguis Draxonis powder after pulverizing is preferably 1-15 μm, more preferably 10-15 μm.
Particularly, the traditional Chinese medicine composition for treating the phlegm-blood stasis type obesity is prepared by drying the mixed concentrated solution to prepare mixed medicinal material powder and then uniformly mixing the mixed medicinal material powder with the dragon's blood powder.
In particular, the medicament is in the form of tablets, capsules, pills, powders, granules, syrups, solutions.
Wherein the medicine consists of the traditional Chinese medicine composition and a pharmaceutically acceptable carrier.
The traditional Chinese medicine composition for phlegm-blood stasis combined obesity can be prepared into clinically acceptable oral dosage forms with pharmaceutically acceptable auxiliary materials according to the traditional or modern production process. Such as capsule, tablet, granule, pill, oral liquid, etc.
The pharmaceutically acceptable excipient, which is an inactive ingredient of the pharmaceutical preparation, may be a pharmaceutically acceptable carrier selected from the group consisting of, for example, starch, dextrin, lactose, microcrystalline fiber, gelatin, sucrose, magnesium stearate and the like, in the handbook of pharmaceutical excipients (handbook of pharmaceutical excipients, 2 nd edition, edited by a.side and p.j.weller; published by american pharmaceutical association, washingtonana and pharmaceutical press, London, 1994).
The medicine needs to be taken for a long time clinically, is prepared into a solid preparation which is convenient to store and take by patients, and is more suitable for market demands. The preferable dosage forms are capsules, granules, tablets, pills, powders, oral liquids and the like.
In particular, the weight ratio of the traditional Chinese medicine composition to the total weight of the medicine or the health care product is 0.01-100: 100, namely the traditional Chinese medicine composition accounts for 0.01 to 100 percent of the medicine or the health care product.
The medicine can be prepared into various dosage forms by adopting a method known in the art, such as tablets, capsules, pills, powder, granules, syrup, decoction and the like.
The invention also provides a method for treating phlegm-blood stasis mutual-combination type obesity, wherein the oral administration is carried out 1-2 times per day, 3-6 g (composition and dry) is carried out each time, the pregnant woman is prohibited from taking the composition, spicy food and wine are prohibited during the administration period, and the weight/BMI is obviously improved after the composition is continuously used for 2-4 weeks.
The traditional Chinese medicine composition for phlegm-blood stasis mutual-bonding obesity has the following advantages:
1. the invention develops and develops the new medicinal value of the traditional Chinese medicine composition (Qi longxue Maijian prescription), and the traditional Chinese medicine composition is used for preventing, relieving and treating diseases such as obesity and complications caused by obesity, and particularly has obvious curative effect on symptomatic treatment aiming at the disease cause of phlegm-blood stasis type obesity.
2. The traditional Chinese medicine composition is compounded by a plurality of traditional Chinese medicine components, wherein the active components of the medicines have mutual synergistic effect, directly regulate and control the pathological mechanism of in-vivo lipogenesis and accumulation, and adopt multi-link comprehensive treatment aiming at the formation reason of phlegm-stasis mutual type obesity, thereby effectively preventing obesity and other diseases and complications caused by obesity.
3. The traditional Chinese medicine composition (Qi longxue Maijian formula) has obvious curative effect on obesity, especially obesity caused by intermingled phlegm and blood stasis, has the effect of dredging collaterals, and is especially suitable for the states of intermingled phlegm and blood stasis and blocked channels.
4. The traditional Chinese medicine composition (Qi Long blood vessel strengthening formula) for treating phlegm and blood stasis interlocking type obesity prepared by the invention has the advantages of no toxic or side effect, simple preparation process, stable product quality, obvious effect and convenience in use, and overcomes the defect of the market of Chinese patent medicines for treating phlegm and blood stasis interlocking type obesity.
5. The traditional Chinese medicine composition for treating obesity (Qi longxue Maijian prescription) achieves the purpose of improving obesity by reducing phlegm, activating blood, descending turbid and dredging collaterals, focuses on the improvement effect on the syndrome of phlegm and blood stasis, and can effectively prevent other diseases and complications caused by further obesity.
6. The traditional Chinese medicine composition (Qi longxue Maijian prescription) has the advantages of rich raw material sources, low price, safe clinical use, simple preparation process, capability of being prepared into various dosage forms, small dosage, convenient use and low cost, reduces the treatment cost of obesity, saves the clinical health medical cost, is suitable for market popularization and application, and is beneficial to more patients or weight-losing patients, so the traditional Chinese medicine composition is easy to popularize.
Detailed Description
The invention will be further described with reference to specific embodiments, and the advantages and features of the invention will become apparent as the description proceeds. These examples are illustrative only and do not limit the scope of the present invention in any way. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention, and that such changes and modifications may be made without departing from the spirit and scope of the invention.
The beneficial effects of the drug of the present invention are further illustrated by the following test examples, which include pharmacodynamic tests of the drug of the present invention.
Example 1 preparation of Qi Longxue Mai Jian granule
1) Preparing raw material medicaments according to the following weight ratio (unit: x 10g)
Rhizoma Coptidis 6, Olibanum 12, Myrrha 12, sanguis Draxonis 6, rhizoma Pinelliae Preparata 9, fructus Trichosanthis 15, herba Gynostemmatis 30, Poria 30, and Ningpo Yam rhizome 30, wherein the Olibanum is vinegar parched Olibanum; myrrha is prepared by parching Myrrha with vinegar;
2) cleaning raw material medicines including coptis chinensis, frankincense, myrrh, pinellia ternate, snakegourd fruit, gynostemma pentaphylla, poria cocos and dioscorea nipponica, putting the cleaned raw material medicines into a multifunctional traditional Chinese medicine extraction kettle, uniformly mixing, adding tap water to soak for 30min (usually 20-90min), wherein the ratio of the weight of the added tap water to the weight (dry weight) of the medicinal material mixture is 9:1 (typically 1-15: 1);
3) starting a power supply of the multifunctional extraction kettle to heat, heating to 100 ℃, keeping the temperature, extracting for 3 hours at constant temperature, and filtering to obtain a first extracting solution for later use;
4) adding tap water into the filter residue for 1 time, heating and extracting for 1 time, wherein the ratio of the weight of the tap water added to the weight (dry weight) of the medicinal material mixture is 5:1 (generally 1-15:1), heating and extracting at 100 ℃ for 3h, and filtering to obtain a second extracting solution;
the heating and extracting temperature is not limited to 100 ℃, and other temperatures (such as 60-100 ℃, preferably 90-100 ℃) are all suitable for the invention.
5) Mixing the extractive solutions obtained in 2 times, making into mixed extractive solution, and vacuum evaporating and concentrating in a vacuum high-energy evaporation concentrator under reduced pressure to obtain concentrated extract, wherein the relative pressure of the reduced pressure concentration is-0.07 MPa (one atmosphere is 0, and the pressure during reduced pressure concentration is controlled to be-0.07 MPa relative to one atmosphere), the concentration temperature is 80 deg.C, and the mixed extractive solution is concentrated to obtain mixed concentrated solution with relative density of 1.2;
in addition to the concentration by evaporation under reduced pressure, the concentration method known in the art is suitable for the present invention, such as heating and evaporation under normal pressure. The relative density of the mixed concentrate is 1.05-1.5 and is suitable for the invention.
6) Drying the mixed concentrated solution at 45-50 deg.C until water content is lower than 5% (usually 1-4%), pulverizing, and sieving with 180 mesh sieve to obtain mixed medicinal powder;
7) micronizing sanguis Draxonis with micronizer to obtain sanguis Draxonis superfine powder with particle diameter less than 15 μm (usually 10-15 μm);
the superfine grinding is taken as an example for explaining the grinding of the dragon blood in the invention, and other grinding treatments are also applicable to the invention.
8) Mixing the mixed medicinal material powder, the dragon's blood ultrafine powder and the auxiliary material dextrin, using ethanol as an adhesive, granulating and drying to obtain the traditional Chinese medicine Qi longxue Mai Jian granule for treating obesity.
Example 2 preparation of Qi LONG XUEMAIJIAN pill
1) Preparing raw material medicaments according to the following weight ratio (unit: x 10g)
Coptis root 3, frankincense 6, myrrh 12, dragon's blood 9, rhizoma pinellinae praeparata 6, trichosanthes kirilowii 9, gynostemma pentaphylla 15, poria cocos 15 and dioscorea nipponica 30
2) Rinsing the medicinal materials including coptis chinensis, frankincense, myrrh, pinellia ternate, snakegourd fruit, gynostemma pentaphylla, poria cocos and dioscorea nipponica, putting the rinsed medicinal materials into a multifunctional traditional Chinese medicine extraction kettle, uniformly mixing the rinsed medicinal materials and the traditional Chinese medicine extraction kettle, adding tap water, and soaking the mixture for 60min, wherein the ratio of the weight of the added tap water to the weight (dry weight) of the medicinal material mixture is 6: 1;
3) starting a power supply of the multifunctional extraction kettle to heat, keeping the temperature at 80 ℃, extracting for 5 hours at constant temperature, and then filtering to obtain a first extracting solution for later use;
4) adding tap water into the filter residue for 2 times, and heating and extracting for 2 times, wherein the ratio of the weight of the tap water added to the weight (dry weight) of the medicinal material mixture is 4: 1 (generally 1-15:1), heating and extracting at 80 deg.C for 2h, and filtering to obtain 2 extractive solutions;
5) mixing the extractive solutions for 3 times, making into mixed extractive solution, and vacuum evaporating and concentrating in a vacuum high-energy evaporation concentrator under reduced pressure to obtain concentrated extract, wherein the relative pressure of the reduced pressure concentration is-0.05 MPa (one atmosphere is 0, and the pressure during reduced pressure concentration is controlled to be-0.05 MPa relative to one atmosphere), and concentrating the mixed extractive solution to obtain mixed concentrated solution with relative density of 1.3;
6) spray drying the mixed concentrated solution to obtain mixed medicinal powder;
7) micronizing sanguis Draxonis with micronizer to obtain sanguis Draxonis superfine powder with particle diameter less than 15 μm (usually 1-15 μm);
8) mixing the mixed medicinal material powder, the dragon's blood ultrafine powder and the auxiliary material refined honey, uniformly stirring, putting into a pill making machine for making pills, and then drying to obtain the traditional Chinese medicine Qi Longxue Mai Jian concentrated pill for treating obesity.
Example 3 preparation of Qi LONG XUEMAIJIAN tablet
1) Preparing raw material medicaments according to the following weight ratio (unit: x 10g)
Coptidis rhizoma 9, Olibanum 12, Myrrha 6, sanguis Draxonis 3, rhizoma Pinelliae Preparata 9, fructus Trichosanthis 15, herba Gynostemmatis 30, Poria 30, Ningpo Yam rhizome 15
2) Cleaning raw material medicines including coptis chinensis, frankincense, myrrh, snakegourd fruit, gynostemma pentaphylla, poria cocos and yam, putting the cleaned raw material medicines into a multifunctional traditional Chinese medicine extraction kettle, adding tap water to soak for 20min (usually 20-90min), wherein the ratio of the weight of the added tap water to the weight (dry weight) of the medicinal material mixture is 12:1 (usually 1-15: 1);
3) starting a power supply of the multifunctional extraction kettle to heat, heating to 80 ℃, keeping the temperature for extracting for 5 hours at constant temperature, and then filtering to obtain a first extracting solution for later use;
4) then adding tap water into the filter residue for 3 times, and heating and extracting for 3 times, wherein the ratio of the weight of the tap water added to the weight (dry weight) of the medicinal material mixture in each time is 1: 1 (generally 1-15:1), heating and extracting at 90 deg.C for 1h, and filtering to obtain 3 extractive solutions;
5) mixing the extractive solutions for 4 times, making into mixed extractive solution, and vacuum evaporating and concentrating in a vacuum high-energy evaporation concentrator under reduced pressure to obtain concentrated extract, wherein the relative pressure of the reduced pressure concentration is-0.095 MPa (one atmosphere is 0, and the pressure during reduced pressure concentration is controlled to be-0.095 MPa relative to one atmosphere), and the mixed extractive solution is concentrated to obtain mixed concentrated solution with relative density of 1.5;
6) drying the mixed concentrated solution at 45-50 deg.C until water content is lower than 5% (usually 1-4%), pulverizing, and sieving with 100 mesh sieve to obtain mixed medicinal powder;
7) micronizing sanguis Draxonis with micronizer to obtain sanguis Draxonis superfine powder with particle diameter less than 15 μm (usually 1-10 μm);
8) mixing the mixed medicinal material powder, the dragon's blood ultrafine powder and the auxiliary material dextrin, granulating by using ethanol, drying, and tabletting by using a tabletting machine to obtain the traditional Chinese medicine Qi Longxue Mai Jian tablet for treating phlegm-blood stasis type obesity.
Example 4 preparation of Qi LONG XUEMAIJIAN Capsule
1) Preparing raw material medicaments according to the following weight ratio (unit: x 10g)
Coptis root 3, frankincense 15, myrrh 15, dragon's blood 3, rhizoma pinellinae praeparata 3, trichosanthes kirilowii 6, gynostemma pentaphylla 30, poria cocos 10 and dioscorea nipponica 30
2) Cleaning raw material medicines including coptis chinensis, frankincense, myrrh, snakegourd fruit, gynostemma pentaphylla, poria cocos and yam, putting the cleaned raw material medicines into a multifunctional traditional Chinese medicine extraction kettle, adding tap water, and soaking for 90min (usually 20-90min), wherein the weight ratio of the added tap water to the weight (dry weight) of the medicinal material mixture is 6:1 (usually 1-15: 1);
3) starting a power supply of the multifunctional extraction kettle to heat, heating to 80 ℃, keeping the temperature for extracting for 4 hours at constant temperature, and then filtering to obtain a first extracting solution for later use;
4) adding tap water into the filter residue for 1 time, and heating and extracting for 1 time, wherein the ratio of the weight of the added tap water to the weight (dry weight) of the medicinal material mixture is 5:1 (generally 1-15:1), heating and extracting at 80 deg.C for 3h, and filtering to obtain a second extractive solution;
5) mixing the extractive solutions obtained in 2 times, making into mixed extractive solution, and vacuum evaporating and concentrating in a vacuum high-energy evaporation concentrator under reduced pressure to obtain concentrated extract, wherein the relative pressure of the reduced pressure concentration is-0.07 MPa (one atmosphere is 0, and the pressure during reduced pressure concentration is controlled to be-0.07 MPa relative to one atmosphere), and concentrating the mixed extractive solution to obtain mixed concentrated solution with relative density of 1.1; the concentration temperature was 80 ℃.
6) Freeze-drying the mixed concentrated solution, then crushing and sieving by a 100-mesh sieve to prepare mixed medicinal material powder;
7) micronizing sanguis Draxonis with micronizer to obtain sanguis Draxonis superfine powder with particle diameter less than 15 μm (usually 1-10 μm);
8) the traditional Chinese medicine Qi longxue Mai jian capsule for treating the phlegm-blood stasis type obesity is prepared by mixing the mixed medicinal material powder, the dragon's blood ultramicro powder and the auxiliary material microcrystalline fiber and then filling the mixture into a gelatin hard capsule.
Example 5 preparation of Qi Longxue Mai Jian oral liquid
1) Preparing raw material medicaments according to the following weight ratio (unit: x 10g)
Rhizoma Coptidis 12, Olibanum 6, Myrrha 6, sanguis Draxonis 12, rhizoma Pinelliae Preparata 9, fructus Trichosanthis 15, herba Gynostemmatis 10, Poria 30, and Ningpo Yam rhizome 10
2) Cleaning raw material medicines including coptis chinensis, frankincense, myrrh, snakegourd fruit, gynostemma pentaphylla, poria cocos and yam, putting the cleaned raw material medicines into a multifunctional traditional Chinese medicine extraction kettle, adding tap water, and soaking for 60min (usually 20-90min), wherein the ratio of the weight of the added tap water to the weight (dry weight) of the medicinal material mixture is 9:1 (usually 1-15: 1);
3) starting a power supply of the multifunctional extraction kettle to heat, heating to 100 ℃, keeping the temperature for extracting for 3 hours at constant temperature, and then filtering to obtain a first extracting solution for later use;
4) adding tap water into the filter residue for 2 times, and heating and extracting for 2 times, wherein the ratio of the weight of the tap water added to the weight (dry weight) of the medicinal material mixture is 5:1 (generally 1-15:1), heating and extracting at 100 deg.C for 3 hr, and filtering to obtain 2 extractive solutions;
5) mixing the extractive solutions for 3 times, making into mixed extractive solution, and vacuum evaporating and concentrating in a vacuum high-energy evaporation concentrator under reduced pressure to obtain concentrated extract, wherein the relative pressure of the reduced pressure concentration is-0.07 Pa (one atmosphere is 0, and the pressure during reduced pressure concentration is controlled to be-0.07 MPa relative to one atmosphere), and concentrating the mixed extractive solution to obtain mixed concentrated solution with relative density of 1.1; the concentration temperature was 100 ℃.
6) Micronizing sanguis Draxonis with micronizer to obtain sanguis Draxonis superfine powder with particle diameter less than 15 μm (usually 1-10 μm);
7) adding the dragon's blood ultramicro powder into the mixed concentrated solution, stirring, uniformly mixing, and subpackaging in plastic composite film packages to prepare the traditional Chinese medicine Qi Longxue Mai Jian oral liquid (Qi Longxue Mai Jian Tang) for treating obesity.
Test example 1 weight Effect on animal model with high fat diet
1. Material
1.1 Experimental animals and raising
48 APOE-/-male mice 8 weeks old were selected, and the body mass (20 + -2) g (purchased from Beijing Wintolite laboratory animal technology Co., Ltd., license number of laboratory unit: SYXK (Jing) 2014-0041, license number of laboratory animal production: SCXK (Jing) 2016-0006) were selected. The experiment was started after 1 week of adaptive feeding (SPF scale). Feeding in II-level animal rooms of Guangan Hospital, separating male and female animals into cages, providing regular illumination (12 hours each day and night) for 5 animals per cage, drinking sterile water, keeping the ambient temperature at 20 +/-2 ℃, keeping the relative humidity at 45% -50%, and ventilating under good conditions.
40 APOE-/-mice were fed on high-fat diet for 14 weeks; 8 APOE-/-mice were fed on regular chow for 14 weeks; high-fat feed is purchased from Beijing Huafukang Biotech limited, and common feed is provided by the laboratory animal center of Guangan Hospital.
Formula of high fat feed (also called western diet): casein, methionine, corn starch, maltodextrin, sucrose, cellulose, corn oil, anhydrous butter, mineral mixture, calcium carbonate, vitamin mixture, choline bitartrate, cholesterol, antioxidant, etc., and the nutritional ingredients are shown in Table 1.
The raw material composition of the feed (namely the common feed) is maintained as follows: corn, soybean meal, fish meal, flour, bran, salt, ammonium calcium phosphate, stone powder, various vitamins, various trace elements, amino acid and the like, and the nutritional ingredients are shown in the table 1.
TABLE 1 composition Table of mouse standard diet and high fat diet
Figure BDA0002645819710000141
1.2 major drugs and reagents
(1) Qi longxue Mai Jian Fang: coptis root 6g (finished product batch number: 17020003), frankincense 12g (finished product batch number: 17010011), myrrh 12g (finished product batch number: 17080101), pinellia tuber 9g (finished product batch number: 17110160), trichosanthes fruit 15g (finished product batch number: 17050141), yam 30g (finished product batch number: 17090117), gynostemma pentaphylla 30g (finished product batch number: 17100026), poria cocos 30g (finished product batch number: 17100101) and dragon's blood 6g (finished product batch number: 1701006). The formula of Qi longxue Mai Jian Fang is provided by Guanan Hospital pharmacy department of Chinese academy of science of traditional Chinese medicine, and is prepared into dry active composition granules.
(2) Atorvastatin calcium tablet (lipitor): specification 20 mg/tablet × 7 tablets/box, pfeiy pharmaceutical limited, approved literature: the national drug standard J20120049;
1.3 Main instruments
A YB502 precision electronic balance (shanghai precision instruments ltd); 3-18K high speed refrigerated centrifuge (Sigma, Germany); ultra low temperature refrigerator at-80 ℃ (Sanyo, Japan); BCD-190TMPK4 deg.C refrigerator (Haier, China); Milli-Q ultrapure water purification apparatus (Merck Millipore, USA); SIM-F140AY65 automatic ice maker (Sanyo, Japan). Shanghai temple DS-788 electronic scale.
2. Method of producing a composite material
2.1 Experimental animal grouping and administration method
2.1.1 groups of Experimental animals
40 APOE-/-male mice of 8 weeks are randomly divided into 5 groups of model group, atorvastatin calcium group and traditional Chinese medicine Qi longxue Jianfang large, medium and small dose group, each group comprises 8 mice, and the mice are fed with high fat feed; 8 APOE-/-male mice, normal (blank) group, were fed with normal diet.
2.1.2 drug formulation
(1) Qi longxue Mai Jianfang (granule), ground, prepared into suspension with physiological saline for clinical use, and stored in a refrigerator at 4 ℃.
(2) Atorvastatin calcium tablets are ground into powder, prepared into suspension with physiological saline for use in clinic, and stored in a refrigerator at 4 ℃.
2.1.3 methods of administration and dosages
Normal group and model group are irrigated with normal saline, atorvastatin calcium group is irrigated with atorvastatin calcium solution, and the traditional Chinese medicine Qi LONG XUE MAI JIAN formula is irrigated with suspension prepared from traditional Chinese medicine granules with corresponding dosage. The gavage time was 14 weeks. The gavage dose was 0.1ml/10g/d and was adjusted during the experiment according to the weekly body weight measurements.
(3) Normal group: the mice are subjected to intragastric administration by using normal saline, and the dosage is 0.1ml/10g/d each time and once a day;
(4) model group: the mice are subjected to intragastric administration by using normal saline, and the dosage is 0.1ml/10g/d each time and once a day;
(5) atorvastatin calcium group: the mice are administrated with atorvastatin calcium solution (human (according to 60kg) with the dosage of 20mg/d, prepared by physiological saline) and are perfused with stomach, 0.1ml/10g/d is given each time, and the administration is carried out once a day;
(6) the qi longxue Mai Jian Fang large dose group: the traditional Chinese medicine Qi longxue Maijian formula is administered for gastric perfusion, the clinical dosage is 20 times, and the dosage is 0.1ml/10g/d each time and once a day;
(7) the dosage group in the formula of qi longxue Mai jian is as follows: the traditional Chinese medicine Qi longxue Maijian formula is administered for gastric perfusion, the clinical dosage is 10 times, and the dosage is 0.1ml/10g/d each time and once a day;
(8) the qi longxue mai Jian Fang small dose group: the traditional Chinese medicine Qi longxue Maijian formula is administered for gastric perfusion, the clinical dosage is 5 times, and the dosage is 0.1ml/10g/d each time and once a day.
2.2 mouse weight measurement method
From 0 week, all mice were weighed once every other week, placed on an animal electronic scale using a clean container, peeled, and then weighed one by one, and accurately recorded until all mice were measured, with the results of the weight measurements shown in table 2.
2.3 fat isolation and weighing of mouse epididymis
After 14 weeks, the abdomen and the thoracic cavity were cut along the midline of the abdomen, the tip of the syringe was inserted into the left ventricle while the right auricle was cut, the left was perfused with pre-cooled ice saline, the epididymal fat on both sides was completely removed, blood stain was washed in saline, excess water was drained with filter paper, and the weight of the epididymal fat in mice was weighed as shown in table 3.
2.4 data analysis
The experimental data were statistically analyzed using the SPSS24.0 software package, and the measured data were expressed as mean ± standard deviation: comparing the groups, and analyzing by using single-factor variance when the group accords with normal distribution, wherein the difference is that p is less than 0.05, and the difference has statistical significance; when the distribution is abnormal, a nonparametric test is adopted, and the difference that p is less than 0.05 has statistical significance.
3. Results
3.1 Qi Longxue Mai Jian Fang Pao ApoE-/-Effect of mouse body weight
Table 2 table of weight change of mice
Figure BDA0002645819710000161
Note: model group VS blank, #: p < 0.01; experimental group VS model group, x: p < 0.05; **: p <0.01
From the measurement results in table 2, it is clear that: at week 0, there was no difference between the experimental groups compared to the model group (P > 0.05). Over time, the weight average of each group increased, and the magnitude of weight gain was greater for the model group than for the blank group. The increase of the body weight of each experimental group is smaller than that of the model group. At week 14, the model group further gained weight, with a weight average greater than that of the blank group (P < 0.01). The atorvastatin calcium group and the Qi longxue Mai are large in formula, the weight of the middle-dose group is obviously lower than that of the model group (P is less than 0.05), the weight average of the Qi longe Mai is lower than that of the model group, and the difference is not statistically significant (P is more than 0.05).
3.2 influence of Qi Longxue Mai Jian Fang on the weight of epididymal fat in ApoE-/-mice
TABLE 3 mouse epididymal fat weight
Figure BDA0002645819710000171
Note: model group VS blank, #: p < 0.01; experimental group VS model group, x: p < 0.05; **: p <0.01
According to the above table, after ApoE-/-mice eat high-fat diet, fat accumulation occurs, the weight of epididymal fat is obviously increased compared with that of a control group (P <0.01), the weight of atorvastatin calcium is obviously reduced after the atorvastatin calcium is administrated (P < 0.05), the weight of epididymal fat is more obviously reduced in a large dose group of QILONGMAIJIAN prescription (P <0.01), and a small dose and a medium dose show a certain reduction trend, but do not show statistical significance (P > 0.05). May be related to a certain degree of individual variability of epididymal fat and a relatively small sample size per group. However, the experimental result can prove that the Qi Longxue Maijian formula has obvious effect on reducing the weight of epididymal fat.
Experimental example 2 Qi Longxue Mai Jian Fang for treating obesity
Patients who have got a doctor who is Liu somebody, are male and 45 years old, and have a diagnosis in 8-12 months in 2014 mainly because of the 'weight increase of 10 years'.
The current medical history: the weight of the patient is about 80kg before the patient is treated, and the weight of the patient gradually increases over 10 years due to life rule disorder and emotional anxiety, and gradually becomes stable to about 95 kg. No diagnosis and treatment are given. 2013-7-15, the biochemical blood TG 3.12 is detected in vivo, and the fatty liver (mild) is indicated by abdominal ultrasound. In the last 1 year, the food rhythm, light diet and moderate activity are adjusted, and the traditional Chinese medicine for tonifying qi and spleen is taken once, but the weight does not change obviously.
The following symptoms are marked: shortness of breath, lassitude, poor sleep, desire to be small, loose stool.
History of the past: the hypertension is about 150/100mmHg at the maximum in 3 years, is about 130/86mmHg at ordinary times, and is not regularly monitored and taken.
Family history: both parents are obese.
Deny the history of trauma and allergy.
Personal history: addiction to greasy food, occasional drinking, denial of history of smoking.
Physical examination and four diagnostic methods of traditional Chinese medicine: 168cm in height, 96.3kg in weight, clear emotion, free expression, symmetrical body, correct answers, clear voice, dark lip color, purple, dark and swollen tongue, tooth marks and ecchymosis, yellow, thick and greasy coating, and wiry and smooth pulse.
And (3) Western diagnosis: 1. obesity; 2. hyperlipidemia; 3. fatty liver; 4. hypertension is caused.
Traditional Chinese medicine diagnosis: obesity (syndrome of intermingled phlegm and blood stasis).
Therapeutic principle: resolve phlegm, activate blood, descend turbidity and dredge collaterals.
Prescription: qi Longxue Mai Jian Fang.
The composition and decoction method of the medicine are as follows:
coptis root 6g, frankincense 10g, myrrh 10g, dragon's blood powderSeparate punching6g, 9g of rhizoma pinellinae praeparata, 30g of fructus trichosanthis, 30g of gynostemma pentaphylla, 15g of poria cocos and 30g of dioscorea nipponica. Decoct 28 with water for oral administration. Order to keep diet light and moderate activity.
Second visit (9 months and 9 days 2014): 91.3kg of body weight, short breath, hypodynamia, better lassitude, still slightly obvious lassitude, slightly better sleep, less frequent dreams, increased frequency of stool formation and sometimes loose stool. A purple, dark and swollen tongue with teeth marks and ecchymosis, a yellow and greasy coating and a wiry and slippery pulse. The decoction is decocted with 28 doses of water, the above is slightly modified, and the decoction is taken with the same cautions.
Three diagnoses (10 months and 14 days 2014): the drug is stopped for 1 week in the holiday, the weight is 87.6kg, the shortness of breath and the hypodynamia are obviously improved, the patient still has slight lassitude, dreams happen occasionally during sleep, and loose stools happen occasionally. Dark red and swollen tongue with ecchymosis, thin and yellow coating, and wiry and smooth pulse. The decoction is decocted with 28 doses of water, the above is slightly modified, and the decoction is taken with the same cautions.
Four diagnostic methods (11 months and 11 days 2014): the weight is 84.5kg, all symptoms basically disappear, the regulation and treatment is continued for more than 3 months according to the addition and subtraction of the weight, the weight is gradually reduced to about 75kg, and the people are advised to keep good living habits, light diet and regular exercise. The follow-up did not recur.
The patients shown in the experimental example 2 are diagnosed with the increased weight, the diagnosis of obesity is met, the traditional Chinese medicine syndrome differentiation is met with the syndrome of phlegm-blood stasis, after the qi longxue meridian strengthening formula is taken for a long time, the weight is gradually reduced, the clinical symptoms are obviously improved, and the qi longe blood meridian strengthening formula can effectively improve the obesity, and is particularly suitable for the syndrome of phlegm-blood stasis. And no obvious adverse reaction is found in the long-term use process.
The above-described embodiments of the present invention are merely exemplary and do not limit the scope of the present invention in any way. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention, and that such changes and modifications may be made without departing from the spirit and scope of the invention.

Claims (10)

1. The application of a traditional Chinese medicine composition in preparing a medicine for preventing or/and treating obesity is characterized in that the traditional Chinese medicine composition is prepared from the following raw material medicines: the traditional Chinese medicine composition comprises coptis chinensis, frankincense, myrrh, dragon's blood, rhizoma pinellinae praeparata, fructus trichosanthis, gynostemma pentaphylla, poria cocos and dioscorea nipponica, wherein the raw material medicines comprise the following components in parts by weight: 3-12 parts of coptis chinensis, 6-15 parts of frankincense, 6-15 parts of myrrh, 3-12 parts of dragon's blood, 3-9 parts of rhizoma pinellinae praeparata, 6-15 parts of fructus trichosanthis, 10-30 parts of gynostemma pentaphylla, 10-30 parts of poria cocos and 10-30 parts of dioscorea nipponica.
2. The use of claim 1, wherein said medicament consists of said Chinese medicinal composition and a pharmaceutically acceptable carrier.
3. The application as claimed in claim 1 or 2, wherein the raw material medicines comprise the following components in parts by weight: 3-9 parts of coptis chinensis, 6-12 parts of frankincense, 6-12 parts of myrrh, 3-9 parts of dragon's blood, 6-9 parts of rhizoma pinellinae praeparata, 9-15 parts of fructus trichosanthis, 15-30 parts of gynostemma pentaphylla, 15-30 parts of poria cocos and 15-30 parts of dioscorea nipponica.
4. The use of claim 1 or 2, wherein the Chinese medicinal composition is prepared by the following method:
1) mixing Coptidis rhizoma, Olibanum, Myrrha, rhizoma Pinelliae, fructus Trichosanthis, herba Gynostemmatis, Poria, and Ningpo Yam rhizome, adding water, heating the mixture, extracting for 2-4 times, filtering, and mixing filtrates to obtain mixed extractive solution;
2) concentrating the mixed extract to prepare a mixed concentrated solution;
3) pulverizing sanguis Draxonis to obtain sanguis Draxonis powder;
4) mixing the concentrated solution with sanguis Draxonis powder.
5. The use according to claim 4, wherein the heat extraction in step 1) is performed according to the following steps:
1A) mixing the raw materials of coptis chinensis, frankincense, myrrh, pinellia ternate, snakegourd fruit, gynostemma pentaphylla, poria cocos and dioscorea nipponica, adding water for soaking, wherein the weight ratio of the added water to the mixed raw materials is 1-15:1, soaking for 20-90min, and then carrying out first heating extraction at the temperature of 60-100 ℃ for 1-5 h;
1B) filtering the mixed system for the first extraction to obtain a first extracting solution; adding water into the residue at least 1 time, and continuously extracting for at least 1 time by heating, wherein the weight ratio of water to mixed raw materials is 1-15:1, the heating extraction temperature is 60-100 deg.C, and the heating extraction time is 1-5 hr;
1C) filtering, and mixing filtrates to obtain the mixed extractive solution.
6. The use according to claim 4, wherein the relative density of the mixed concentrate in step 2) is 1.05 to 1.5.
7. The use according to claim 6, wherein the mixed concentrate has a relative density of 1.1 to 1.5.
8. The use according to claim 6, wherein the mixed concentrate has a relative density of 1.1 to 1.3.
9. The use as claimed in claim 4, wherein the particle size of the sanguis Draxonis powder in step 3) is less than 15 μm.
10. Use according to claim 1 or 2, wherein the medicament is in the form of tablets, capsules, pills, powders, granules, syrups, solutions.
CN202010854230.XA 2020-08-24 2020-08-24 Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity Active CN112089783B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010854230.XA CN112089783B (en) 2020-08-24 2020-08-24 Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010854230.XA CN112089783B (en) 2020-08-24 2020-08-24 Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity

Publications (2)

Publication Number Publication Date
CN112089783A CN112089783A (en) 2020-12-18
CN112089783B true CN112089783B (en) 2022-03-22

Family

ID=73754233

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010854230.XA Active CN112089783B (en) 2020-08-24 2020-08-24 Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity

Country Status (1)

Country Link
CN (1) CN112089783B (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103494188A (en) * 2013-09-03 2014-01-08 陈翔 Blood-lipid-lowering pure traditional Chinese medicine solvent
CN110538295A (en) * 2019-09-25 2019-12-06 万红 traditional Chinese medicine composition for patients with damp-heat retention and abdominal obesity and preparation method thereof

Also Published As

Publication number Publication date
CN112089783A (en) 2020-12-18

Similar Documents

Publication Publication Date Title
CN103479963A (en) Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof
CN103100025A (en) Drug composition for tonifying kidney and yang and preparation method thereof
CN103142916B (en) Medicament for preventing and treating senile dementia and preparation method thereof
CN112089784A (en) Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis
CN101890062B (en) Use of nardostachys chinensis batal and extract thereof in preparation of medicaments for treating gastric ulcer
CN103977390B (en) A kind of preparation method and its usage of ginger onion medicated wine composition
CN112057535B (en) Preparation method of traditional Chinese medicine composition for preventing or/and treating dyslipidemia
CN112089783B (en) Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity
CN111135235A (en) A composition for preventing and relieving acute alcoholism or alcoholic intoxication
CN105999058B (en) Bidens bipinnata lipid-lowering tablet
CN112057536B (en) Traditional Chinese medicine composition for preventing or/and treating dyslipidemia and application thereof
CN102526639A (en) Chinese medicinal composition for treating hyperlipidemia and preparation method thereof
CN107648335B (en) Traditional Chinese medicine composition for regulating atherosclerosis autophagy and apoptosis and preparation method thereof
CN105194355A (en) Traditional Chinese medicine preparation for treating primary hypertension
CN105343808A (en) Traditional Chinese medicine composition with weight reducing effect and preparation method of traditional Chinese medicine composition
CN111084878A (en) Biological medicine and medical total nutrient food for lung and respiratory system diseases and preparation method thereof
CN114712466B (en) Medicine with weight-reducing and beautifying effects and preparation method thereof
CN114767816B (en) Traditional Chinese medicine composition for treating coronary heart disease and preparation method thereof
CN108743885A (en) A kind of Chinese medicine and preparation method thereof for treating Diabetic Macrovascular Complications
CN108478701A (en) A kind of lozenge of strengthen immunity
CN102552724A (en) Chinese medicine composite for curing hypertension
CN106728828A (en) A kind of Chinese medicine preparation and its preparation technology for treating coronary heart disease
CN1209139C (en) Traditional Chinese medicine for curing vascular dementia and its preparing method
CN105833109B (en) Moringa oleifera-containing composition for treating hyperglycemia and hyperlipidemia and preparation method and application thereof
CN104306553B (en) A kind of food of reducing blood lipid, health care product or pharmaceutical composition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant